Cargando…

Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic

PURPOSE: There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korobelnik, Jean-François, Loewenstein, Anat, Eldem, Bora, Joussen, Antonia M., Koh, Adrian, Lambrou, George N., Lanzetta, Paolo, Li, Xiaoxin, Lövestam-Adrian, Monica, Navarro, Rafael, Okada, Annabelle A., Pearce, Ian, Rodríguez, Francisco J., Wong, David T., Wu, Lihteh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179379/ https://www.ncbi.nlm.nih.gov/pubmed/32328757 http://dx.doi.org/10.1007/s00417-020-04703-x

Ejemplares similares

Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure
por: Korobelnik, Jean-François, et al.
Publicado: (2021)

CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: An Expert Panel Consensus
por: Wong, Tien Yin, et al.
Publicado: (2020)

Communicating with patients requiring anti-VEGF intravitreal injections and their families during the COVID-19 pandemic: an update
por: Korobelnik, Jean-François, et al.
Publicado: (2021)

Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases
por: Lanzetta, Paolo, et al.
Publicado: (2017)

Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review
por: Okada, Mali, et al.
Publicado: (2021)

SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY
por: Wong, David T., et al.
Publicado: (2020)

The ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international survey
por: Veritti, Daniele, et al.
Publicado: (2023)

MANAGEMENT OF RETINAL PIGMENT EPITHELIUM TEAR DURING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
por: Mitchell, Paul, et al.
Publicado: (2021)

Current status and practical considerations of artificial intelligence use in screening and diagnosing retinal diseases: Vision Academy retinal expert consensus
por: Chou, Yu-Bai, et al.
Publicado: (2023)

The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus
por: Danese, Carla, et al.
Publicado: (2023)

Treatment algorithm with dexamethasone intravitreal implant in patients with diabetic macular edema
por: Epstein, David, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose
por: Veritti, Daniele, et al.
Publicado: (2023)

Communicating with patients with nAMD and their families during the COVID-19 pandemic
por: Korobelnik, Jean-François, et al.
Publicado: (2020)

Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits
por: Ramon, Dan, et al.
Publicado: (2018)

Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study
por: Augustin, Albert J., et al.
Publicado: (2015)

The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab
por: Dikmetas, Ozlem, et al.
Publicado: (2013)

Macular Hole following Intravitreal Bevacizumab Injection in Choroidal Neovascularization Caused by Age-Related Macular Degeneration
por: Moisseiev, Elad, et al.
Publicado: (2010)

Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
por: Ohji, Masahito, et al.
Publicado: (2020)

Dexamethasone intravitreal implant in the treatment of diabetic macular edema
por: Dugel, Pravin U, et al.
Publicado: (2015)

Inflammatory Complications of Intravitreal Anti-VEGF Injections
por: Cox, Jacob T., et al.
Publicado: (2021)

Impact of intravitreal injection therapy on contrast sensitivity in patients with nAMD and DME
por: Dieke, Sebastian, et al.
Publicado: (2023)

INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: Pharmacokinetic Considerations
por: Yang, Yit, et al.
Publicado: (2015)

Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature
por: Chatziralli, Irini, et al.
Publicado: (2021)

Hypotony Maculopathy Related to Anti-VEGF Intravitreal Injection
por: Lima-Fontes, Mário, et al.
Publicado: (2022)

Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems
por: Finger, Robert P., et al.
Publicado: (2020)

A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
por: Fischer, Naomi, et al.
Publicado: (2013)

Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy – a systematic approach to identify and characterize data sources
por: Daien, Vincent, et al.
Publicado: (2019)

Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections
por: Lau, P. ET., et al.
Publicado: (2018)

Intravitreal Trimethoprim and Sulfamethoxazole Toxicity to the Retina of Albino Rabbits
por: Mazza, Orit, et al.
Publicado: (2018)

Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice
por: Giocanti-Auregan, Audrey, et al.
Publicado: (2016)

The Association of Intravitreal Anti-VEGF Injections With Kidney Function in Diabetic Retinopathy
por: Bunge, Casey C., et al.
Publicado: (2023)

Brolucizumab—another anti-VEGF or beyond
por: Sharma, Ashish, et al.
Publicado: (2020)

Pachychoroid: current concepts on clinical features and pathogenesis
por: Castro-Navarro, Veronica, et al.
Publicado: (2020)

Intravitreal Steroids for the Treatment of Retinal Diseases
por: Sarao, Valentina, et al.
Publicado: (2014)

The remote effects of intravitreal anti-VEGF therapy
por: Balta, F, et al.
Publicado: (2016)

Issues with Intravitreal Administration of Anti-VEGF Drugs
por: Schargus, Marc, et al.
Publicado: (2020)

Risk of Posterior Capsular Rupture during Phacoemulsification in Patients with the History of Anti-VEGF Intravitreal Injections: Results from the Pan-American Collaborative Retina Study (PACORES) Group
por: Velez-Montoya, Raul, et al.
Publicado: (2021)

Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
por: Jo, Dong Hyun, et al.
Publicado: (2015)

Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections
por: Levin, Ariana M, et al.
Publicado: (2017)

Concentrations of VEGF and PlGF Decrease in Eyes After Intravitreal Conbercept Injection
por: Zhou, Jun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ahgrcl6v33s7koeqos6p2vd6jh